BioLargo, Inc.
BLGO
$0.219
-$0.0027-1.22%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -16.42% | 22.97% | 45.40% | 85.73% | 91.40% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -16.42% | 22.97% | 45.40% | 85.73% | 91.40% |
| Cost of Revenue | -13.88% | 38.05% | 63.33% | 109.01% | 100.68% |
| Gross Profit | -19.29% | 7.73% | 27.68% | 62.92% | 81.91% |
| SG&A Expenses | 8.19% | 12.62% | 15.51% | 17.08% | 34.45% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -105.88% | -425.00% |
| Total Operating Expenses | -0.88% | 22.49% | 34.60% | 47.75% | 58.56% |
| Operating Income | -68.64% | -21.07% | -3.14% | 30.87% | 10.28% |
| Income Before Tax | -61.52% | -11.44% | 6.48% | 27.82% | 6.67% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -61.52% | -11.44% | 6.48% | 27.82% | 6.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 106.98% | 85.90% | 70.02% | 29.52% | 7.95% |
| Net Income | -40.22% | 14.18% | 31.45% | 45.21% | 12.25% |
| EBIT | -68.64% | -21.07% | -3.14% | 30.87% | 10.28% |
| EBITDA | -70.11% | -19.31% | -1.95% | 31.88% | 11.48% |
| EPS Basic | -34.38% | 17.97% | 34.15% | 47.45% | 15.79% |
| Normalized Basic EPS | -30.56% | 29.63% | 46.15% | 70.77% | 28.00% |
| EPS Diluted | -34.38% | 17.97% | 34.15% | 47.45% | 15.79% |
| Normalized Diluted EPS | -30.56% | 29.63% | 46.15% | 70.77% | 28.00% |
| Average Basic Shares Outstanding | 3.19% | 3.64% | 4.26% | 4.61% | 5.10% |
| Average Diluted Shares Outstanding | 3.19% | 3.64% | 4.26% | 4.61% | 5.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |